SecProbe.io

Filing text and metadata
Intelligence Terminal Search Probe Scores Topics IPO Watchlist Monthly Activity About API

SEC Company Response from NovaBay Pharmaceuticals, Inc. (NBY) (CIK 0001389545) (SDEV) — Jul 22, 2024

NovaBay Pharmaceuticals, Inc. (NBY) (CIK 0001389545)
Date: July 22, 2024 · CIK: 0001389545 · Accession: 0001437749-24-023181

AI Filing Summary & Sentiment

Sentiment
Urgency
Document Type
Confidence
SEC Posture
Company Posture

Summary

Reasoning

File numbers found in text: 333-280423

Date
July 22, 2024
Author
Nicholas Stergis
Form
CORRESP
Company
NovaBay Pharmaceuticals, Inc. (NBY) (CIK 0001389545)

Letter

nby20240716c_corresp.htm

Ladenburg Thalmann & Co. Inc.

640 Fifth Avenue, 4th Floor

New York, New York 10019

July 22, 2024

VIA EDGAR

U.S. Securities and Exchange Commission

Division of Corporation Finance

Office of Life Sciences

100 F Street, N.E.

Washington, DC 20549

Attn:

Jimmy McNamara

Re:

NovaBay Pharmaceuticals, Inc. (the “Company”)

Registration Statement on Form S-1

File No. 333-280423

Ladies and Gentlemen:

Ladenburg Thalmann & Co. Inc. (“Ladenburg”), as representative of the underwriters for the referenced offering, hereby concurs in the request by NovaBay Pharmaceuticals, Inc. that the effective date of the above-referenced registration statement be accelerated to 5:30 p.m. (Eastern Time), or as soon as practicable thereafter, on Tuesday, July 23, 2024, pursuant to Rule 461 under the Securities Act. Ladenburg affirms that it is aware of its obligations under the Securities Act in connection with this offering.

Very truly yours,
Ladenburg Thalmann & Co. Inc.

Show Raw Text
CORRESP
1
filename1.htm

	nby20240716c_corresp.htm

Ladenburg Thalmann & Co. Inc.

640 Fifth Avenue, 4th Floor

New York, New York 10019

July 22, 2024

VIA EDGAR

U.S. Securities and Exchange Commission

Division of Corporation Finance

Office of Life Sciences

100 F Street, N.E.

Washington, DC 20549

			Attn:

			Jimmy McNamara

			Re:

			NovaBay Pharmaceuticals, Inc. (the “Company”)

			Registration Statement on Form S-1

			File No. 333-280423

Ladies and Gentlemen:

Ladenburg Thalmann & Co. Inc. (“Ladenburg”), as representative of the underwriters for the referenced offering, hereby concurs in the request by NovaBay Pharmaceuticals, Inc. that the effective date of the above-referenced registration statement be accelerated to 5:30 p.m. (Eastern Time), or as soon as practicable thereafter, on Tuesday, July 23, 2024, pursuant to Rule 461 under the Securities Act. Ladenburg affirms that it is aware of its obligations under the Securities Act in connection with this offering.

			Very truly yours,

			Ladenburg Thalmann & Co. Inc.

			By:

			/s/ Nicholas Stergis

			Nicholas Stergis

			Managing Director, Investment Banking